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1. Introduction
Ischemic heart disease is the most common cause of cardiomyopathy and has been the subject
of intense research and study. However, other rare forms of cardiomyopathy exist and
represent a diagnostic as well as a therapeutic challenge for the clinician. This chapter aims to
review the rare forms of cardiomyopathy, from genetic abnormalities, clinical presentation to
treatment and sudden death prevention.
2. Cardiac sarcoidosis
2.1. Introduction
Sarcoidosis is a multisystem disease characterized by noncaseating granulomas involving
multiple organ systems. Cardiac involvement is relatively rare and ranges from 5 to 40%.
Clinically, patients could have palpitations, atrioventricular block, syncope, shortness of
breath, left ventricular dysfunction and sudden cardiac death. Early recognition and treatment
is important since cardiac involvement portends a poor prognosis and is the second cause of
death in patients with sarcoidosis [1].
2.2. Epidemiology
Sarcoidosis is common in Japan, Ireland, Scandanavia and the United States. Females are
more commonly affected than males.  In  the  United States,  African Americans  are  more
commonly affected and in general have more severe forms of the disease. The age adjusted
annual incidence is highest for African American females in the age group of 30 to 39 years
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and is  at  107  per  100,000  [2].  Clinical  cardiac  involvement  is  reported  to  be  5%,  while
subclinical cardiac involvement detected by imaging studies is in the range of 30-40%, which
matches autopsy series.
2.3. Environmental and genetic factors
The etiology of sarcoidosis remains unknown. The presence of noncaseating granulomas in
the lungs, skin and eyes and clustering of cases in certain occupations (navy personnel,
firefighters at the world trade center) point to an immunological response to environmental
agents or infectious exposure [3, 4]. Mycobacterial DNA and RNA have been found in sarcoid
tissue using polymerase chain reaction, especially the DNA of the mycobacterium tuberculosis
catalase-peroxidase (mKatG) gene [5].
There is familial clustering of the disease, and patients are more likely to have an affect‐
ed member but there is little concordance in organs involved. Class I HLA-B8 and Class II
HLA-DRB1 and HLA-DQB1 alleles have been consistently associated with sarcoidosis [6,
7]. Genome-wide scans for loci associated with sarcoidosis showed the strongest signals in
chromosomes 5p and 5q in African Americans [8]. The strongest signals in Germans were
found in chromosome 6p, which helped identify the butyrophillin-like 2 (BTLN2) gene. This
gene is  a  negative  co-stimulatory molecule  within the  major  histocompatibility  complex
region  [9].  Chromosome  18q22  has  a  strong  link  to  the  presence  of  cardiac  or  renal
sarcoidosis [10]. Likely there is an interaction between environmental exposure and certain
susceptibility genes leading to the development of sarcoidosis. Further research is needed
to clarify such interactions.
2.4. Pathology
The hallmark of sarcoidosis is the presence of noncaseating granulomas. These are compact
collections  of  macrophages  and epithelioid  cells  with  minimal  inflammation  and multi‐
nucleated giant cells. Even though clinical involvement of the heart is reported to be 5%,
autopsy series show cardiac involvement in 25 to 40% of patients [11, 12]. Several recent
imaging studies show that delayed enhancement magnetic resonance imaging (DE MRI) in
patients with histology proven extra-cardiac sarcoidosis could detect cardiac involvement
even in patients with normal electrocardiograms, with cardiac involvement in these studies
ranging from 26-32%, which matches autopsy series [13, 14]. The ventricles are common‐
ly affected, especially the left ventricular (LV) free wall, basal LV, inter-ventricular septum
and conduction system. The heart  could be involved among other systems,  but  isolated
cardiac disease does occur. Endomyocardial biopsy has a low yield (~20%) given the patchy
involvement of the heart muscle. However, it is still needed at times in diagnosis especial‐
ly when other diseases are suspected.
2.5. Clinical features of cardiac sarcoidosis
The heart could be the only organ affected or could be involved in combination with other
systems. The degree of lung involvement does not predict cardiac involvement and cardiac
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involvement can be subclinical without any apparent symptoms. Patients might have non-
specific symptoms like shortness of breath and fatigue. Palpitations are common and could be
due to atrial tachycardia, atrial fibrillation, premature ventricular contractions, sustained and
non-sustained ventricular tachycardia. Rarely patients could present with pericarditis and
cardiac tamponade. The most common criteria used for diagnosing cardiac sarcoidosis is the
2006 revised guidelines of the Japanese Ministry of Health and Wellness [15]. Table 1 gives a
summary of these guidelines.
Advanced atrioventricular block in young patients should prompt search for cardiac sarcoi‐
dosis especially in females [16]. Patients with extra-cardiac sarcoidosis and abnormalities in
the electrocardiogram (ECG) should have at least an echocardiogram performed to look for
left ventricular function, especially when symptoms suggestive of heart failure are present.
However, the JMHW guidelines are not very sensitive and cardiac involvement could be
present even in patients with normal electrocardiograms [17]. There is no consensus about the
best way to screen patients with sarcoidosis for cardiac involvement. In a recent Delphi study
on diagnosing cardiac sarcoidosis, a survey of a group of sarcoidosis experts from different
subspecialties including pulmonologists, cardiologist and electrophysiologists showed a wide
range of practices with most experts utilizing history, physical examination and ECG for
screening. About 75% of experts would not do any further testing in the absence of symptoms
or signs of cardiac involvement along with normal ECG. But when Cardiac sarcoidosis is
suspected, most experts would perform ECG, TTE and cardiac MRI and 67% would order
Holter monitor and cardiac fluorodeoxy-glucose (FDG) PET scan [18]. This reflects the wide
range of clinical practice and the fact that sarcoidosis in general can mimic other diseases and
could stay subclinical. However, it is clear from recent cardiac MRI studies that cardiac
involvement can be present in patients with no cardiac symptoms and a normal ECG in 30%
of patients with biopsy proven extracardiac sarcoidosis [17]. Smedema et al study suggests
that the combination of ECG and MRI is the most cost effective for screening [14]. It is important
to diagnose cardiac sarcoidosis, as patients with cardiac involvement die for heart failure or
sudden cardiac death.
2.6. Laboratory investigations
Laboratory testing in sarcoidosis is non-specific. Patient can have anemia and some might have
hypercalcemia due to activation of vitamin D by macrophages present in granulomas [19].
Elevated angiotensin converting enzyme levels were proposed initially as a diagnostic test and
to follow treatment response. However, there is a wide range of normal in healthy subjects
and it is a poor therapeutic guide [20].
2.7. Electrocardiography (ECG)
The ECG has been used as a screening tool for cardiac involvement in patients with sarcoidosis.
Abnormalities noted include right bundle branch block (RBBB), which can be seen in 20-25%
of patients. Premature ventricular contractions (PVCs), non-sustained ventricular tachycardia
(NSVT) and sustained ventricular tachycardia (VT) could also occur. Inflammation and scar
formation lead to slow conduction and reentry, which is the mechanism of VT in these patients
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[21]. Left bundle branch block and Q waves have been described [22]. Advanced atrioventric‐
ular block (AVB) and complete heart block could occur in up to 20-30% of patients due to the
involvement of the basal LV septum as well as involvement of the AV nodal artery and they
portend a poor prognosis [16]. In patients with symptomatic cardiac sarcoidosis, Shuller et al
showed that fragmentation of the QRS occurs in up to 75% of patients and when combined
with bundle branch block, has 90% sensitivity in detecting cardiac involvement, however, the
study was limited to symptomatic patients [22]. Mehta et al showed that ECG sensitivity could
be as low as 8%. Using 24 hours holter monitoring could help detect abnormalities including
AV block, PVCs and NSVT and has more sensitivity compared to the 12 lead electrocardiogram
(50% vs 8% respectively) [17].
2.8. Endomyocardial biopsy
The  presence  of  noncaseating  granulomas  in  endomyocardial  biopsy  is  diagnostic  of
sarcoidosis. However, endomyocardial biopsy is not sensitive, since the disease is usually
patchy  and  most  commonly  involves  the  left  ventricle.  Of  the  28  patients  with  clinical
Histologic diagnosis group Cardiac sarcoidosis is confirmed when endomyocardial biopsy specimens
demonstrate noncaseating epithelioid granulomas.
Clinical diagnosis group* Cardiac sarcoidosis is diagnosed in the absence of an endomyocardial biopsy
specimen or in the absence of typical granulomas on cardiac biopsy when
extracardiac sarcoidosis has been proven and a combination of majore or minor
diagnostic criteria has been satisfied:
1. More than 2 of the 4 major diagnostic criteria are met OR
2. One of the 4 major criteria and 2 or more of the minor criteria are met.
Major Criteria:
1. Advanced AV block
2. Basal thinning of the ventricular septum
3. Positive cardiac gallium uptake
4. Left ventricular ejection fraction < 50%.
Minor Criteria:
1. Abnormal electrocardiogram findings including ventricular tachycardia,
multifocal frequent premature ventricular contractions, complete right bundle
branch block, pathologic Q waves or abnormal axis deviation
2. Abnormal echocardiogram demonstrating regional wall motion
abnormalities, ventricular aneurysm or unexplained increase in wall thickness.
3. Perfusion defects detected by myocardial scintigraphy
4. Delayed godalinium enhancement of the myocardium on cardiac MRI
scanning
5. Interstitial fibrosis or monocyte infiltration greater than moderate grade by
endomyocardial biopsy.
Table 1. Modified Guidelines for the Diagnosis of Cardiac Sarcoidosis from the Japanese Ministry of Health and
Wellness
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systematic  sarcoidosis  with  documented  cardiomyopathy  who  underwent  endomyocar‐
dial  biopsy  at  John  Hopkins,  only  7  had  noncasesating  granulomas.  If  sarcoidosis  is
suspected, it  is  often recommended to obtain biopsy from other organs like the paratra‐
cheal lymphnodes, skin and even the liver. PET scanning could help detect disease activity
and potential sites for biopsy [23].
The main differential diagnosis to sarcoidosis histologically is giant cell myocarditis. In a series
comparing 42 patients with cardiac sarcoidosis to 73 patients with giant cell myocarditis, nearly
a third of the patients finally diagnosed with cardiac sarcoidosis had no extracardiac involve‐
ment. Underscoring the fact that isolated cardiac involvement does occur [24]. Table 2 lists the
features that help differentiate cardiac sarcoidosis from giant cell myocarditis. Rarely, cardiac
sarcoidosis could only be diagnosed at the time of heart transplantation, further scoring the
difficulties of establishing the diagnosis [25].
Sarcoidosis Giant Cell Myocarditis
African American race 31% 4%
Syncope 31% 5%
AV block 50% 15%
Clinical Presentation
AV block or heart failure
symptoms of > 9 weeks
duration
Usually acute heart failure presentation
Histology Granulomas and fibrosis Eosinophils, myocyte damage and foci oflymphocytic myocarditis
Table 2. Clinical and Histological features comparing Sarcoidosis to Giant Cell Myocarditis.
2.9. Imaging studies in cardiac sarcoidosis
2.9.1. Chest x-ray
Bilateral hilar lymphadenopathy is the most common finding on chest x-ray (CXR). However,
bilateral hilar fullness could be also a sign of pulmonary dilatation secondary to cardiac
involvement or pulmonary hypertension. Cardiomegaly is sometimes noted. When bilateral
hilar lymphadenopathy is found and sarcoidosis is suspected, then high resolution computed
tomography scan is indicated to detect pulmonary parenchymal involvement [19].
2.9.2. Echocardiography
Transthoracic echocardiography (TTE) could be useful in detecting cardiac involvement in
patients diagnosed with extracardiac sarcoidosis. Segmental wall motion abnormalities with
thinning of the ventricular wall and LV dysfunction are common but non-specific findings.
The presence of basal septal thinning in the LV should lead the clinician to consider sarcoidosis
highly in the differential diagnoses especially in young patients with conduction abnormalities
[26]. Aneurysms could be seen especially in the inferior wall. Regional hypertrophy could also
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be found due to inflammation and edema. Right ventricular dysfunction is also seen and in
later stages of pulmonary sarcoidosis, pulmonary hypertension and tricuspid regurgitation
are seen. Mitral regurgitation and rarely pericardial effusion with tamponade physiology
could be the first presentation in patients with sarcoidosis [27]. The sensitivity of TTE in
detecting cardiac involvement in patients with extracardiac sarcoidosis is poor, and ranges
from 14-25% [17, 28].
2.9.3. Magnetic Resonance Imaging (MRI)
Cardiac MRI has emerged as a sensitive modality to detect clinical and subclinical cardiac
sarcoidosis. It has great spatial resolution and can help detect disease activity, presence or
absence of fibrosis, wall motion abnormalities, pericardial involvement as well as right
ventricular involvement. Increased signal intensity on T2 weighted images signifies edema
and inflammation. Focal myocardial thickening can also be due to edema. Delayed enhance‐
ment using godalinium is likely due to fibrosis. The basal and lateral LV walls are most
commonly affected, especially the basal septum [29]. Delayed enhancement MRI is more
sensitive than 201Thallium imaging and 67Ga imaging in detecting subclinical cardiac sarcoi‐
dosis. In a study of 10 patients by Tadamura et al, only 50% of patients with sarcoidosis
exhibited abnormalities on 201Thallium imaging and only 20% had 67Ga uptake while a 100%
of these patients had abnormalities detected by cardiac MRI [30]. Smedema et al studied 58
patients with biopsy proven extracardiac sarcoidosis using the JMHW 1993 criteria as gold
standard. Other modalities studied included ECG, TTE, 201Thallium scintigrams and DE MRI.
Cardiac MRI had a sensitivity of 78-100% and specificity of 64-89% in detecting cardiac
involvement. Cardiac MRI was noted to detect cardiac involvement even in patients with
normal ECG, Echocardiography and 201Thallium Scintigrams [14].
Mehta et al studied 62 patients with extracardiac sarcoidosis using a systematic approach
including  ECG,  Holter  monitoring,  TTE,  18F-FDG  PET  scanning  and  cardiac  MRI.  The
prevalence of cardiac sarcoidosis was 39%. The modified JMHW criteria had a sensitivity
of  33%  and  specificity  of  97%.  Holter  monitoring  was  superior  of  ECG  in  detecting
conduction system abnormalities as well as other ventricular arrhythmias. In the 22 patients
who had both cardiac MRI and 18F-FDG PET scans done, 32% had delayed enhancement
and 5% had edema on T2 images while abnormalities on 18F-FDG PET scan was observed
in 86% of the patients. Cardiac MRI and PET scans can be reasonably done in patients with
suspected cardiac sarcoidosis and can detect subclinical involvement and are more sensitive
than the JWHW criteria [17]. Patel et al studied 81 patients with biopsy proven extracar‐
diac sarcoidosis and used the JMHW modified criteria as well as DE MRI to look for cardiac
involvement. The JMHW identified 10 patients (12%) with cardiac involvement while DE
MRI identified cardiac involvement in 21 patients (26%), only 8 patients overlapped. The
median extent of damage detected by DE MRI was 6.1% of the left ventricle. The basal and
mid ventricular septum showed delayed enhancement in 76% of patients. Furthermore, of
the 4 patients with positive endomyocardial biopsy, all the 4 patients (100%) had abnormal‐
ities detected by DE MRI,  while only 2 patients (50%) met the diagnostic  criteria of  the
JMHW. Patients  with  DE MRI  had 11-fold  increase  risk  of  death  compared  to  patients
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without DE MRI findings [13]. Furthermore, delayed enhancement correlated with disease
duration,  regional  wall  motion  abnormalities,  ventricular  function,  severity  of  mitral
regurgitation and presence of ventricular tachycardia [31].
2.9.4. Radionuclide scintigraphy
201Thallium has been used to detect cardiac involvement in patients with sarcoidosis. Segmen‐
tal areas of decreased perfusion at rest that improve with stress imaging (areas with reverse
distribution) are seen in patients with cardiac sarcoidosis but are not necessarily specific, since
they are also seen in other forms of cardiomyopathy. 201Thallium is more sensitive than 67Ga
scanning in detecting cardiac sarcoidosis, but 67Ga is more specific for sarcoidosis since it
accumulates in inflamed areas and could be used to predict response to therapy and follow
disease activity [32]. 67Ga scanning has the advantage of detecting cardiac as well as extracar‐
diac sarcoidosis and could guide to areas that are more amenable to biopsy [33]. Both modal‐
ities suffer from poor spatial resolution and both are less sensitive than DE MRI in detecting
cardiac sarcoidosis [13, 30]. 99mTc-sestamibi has been used in combination with 67Ga scanning
and could help in showing that areas with increased 67Ga uptake are due to cardiac as opposed
to extracardiac involvement [34].
18- fluoro-2-deoxy-D-glucose PET scanning (18F-FDG PET) has been shown to be of great value
in detecting cardiac involvement in patients with sarcoidosis. 18F-FDG PET is taken up by the
macrophages, lymphocytes and epitheloid cells which are present in the granulomas and is
helpful in detecting active inflammation and following response to corticosteroids treatment.
In a series of 17 patients with biopsy proven extracardiac sarcoidosis, 18F-FDG PET was found
to be the more sensitive in detecting cardiac involvement compared to both 201Thallium and
67Ga scintigraphy. While 67Ga scintigraphy was the least sensitive modality in detecting cardiac
involvement, possibly because of it has a lower spatial resolution compared to 18F-FDG PET.
Most of the abnormalities noted on 18F-FDG PET were found in the basal, mid anteroseptal
and lateral walls and disappeared after treatment with corticosteroids [35]. In another study,
PET and DE MRI were performed in patients with biopsy proven extracardiac sarcoidosis. In
these series, 22 patients had both 18F-FDG PET and DE MRI performed. Of these, abnormalities
in 18F-FDG PET were observed in 86% of the patients while MRI abnormalities were observed
in 36% of the patients. It is possible that the apparent high sensitivity of 18F-FDG PET is due to
its ability to detect active inflammation while DE MRI could only detect edema and scar and
is unable to detect active inflammation [17].
2.10. Therapy
Therapy for cardiac sarcoidosis aims at treating and preventing heart failure, treatment of
conduction  system  disease  and  prevention  of  sudden  cardiac  death.  It  is  important  to
recognize  cardiac  involvement  in  patients  with  sarcoidosis,  since  sudden  cardiac  death
could be the first presentation and is the second leading cause of death in patients with
sarcoidosis [1].
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2.10.1. Medical therapy
Similar to other forms of cardiomyopathy, treatment with angiotensin converting enzyme
inhibitors and angiotensin receptor blockers is important since they have anti-fibrotic prop‐
erties and have been shown to improve survival. β -blockers were also shown to improve
survival in patients with heart failure. Since the initial cardiac lesions are due to granuloma
formation which could progress with time to fibrosis, early recognition and initiation of
corticosteroid treatment is important and could lead to improvement in LV function as well
as achieve control of the arrhythmias [36]. In a Japanese retrospective study of 48 patients with
cardiac sarcoidosis, only patients with pretreatment LVEF > 30% had improvement in their LV
function with corticosteroid therapy, while those with pretreatment LVEF of < 30% showed
little improvement [37]. The exact dose of corticosteroids and the duration of therapy are not
well defined due to the absence of randomized controlled trials. In general, initial dose of 30
to 60 milligrams/day of prednisone is started for 8-12 weeks; with gradual taper to a daily dose
of 5-10 mgs/day of prednisone over 6-12 months is recommended. Relapses could occur in up
to 25% of patients [19, 38]. Use of Methotrexate, cyclosporine or hydroxychoroquine has been
described and could be considered especially in patients with side effects to corticosteroids or
who are not responding to therapy [38].
2.10.2. Device based therapy and the role of electrophysiology study
Patients presenting with heart block due to cardiac sarcoidosis could see improvement with
corticosteroids therapy [36]. However, permanent pacemaker implantation is recommended
even if there is a transient improvement in heart block with corticosteroids therapy [39].
Patients with depressed LVEF < 35%who do not improve with steroid therapy and patients
who present with VT or survive cardiac arrest should undergo defibrillator (ICD) implantation
[39]. Some experts advocate ICD implantation in patients with AVB due to cardiac sarcoidosis
with extensive cardiac involvement on imaging studies even if the LVEF is still preserved [40].
The 2008 guidelines for device based therapy recommend consideration for defibrillator
implantation to be based on LV function, presence of spontaneous or induced ventricular
tachycardia, heart failure status and syncope. Patients with depressed LVEF < 35%, NYHA
Class II-IV heart failure and wide QRS of > 120 milliseconds are candidates for biventricular
defibrillator implantation (BiV ICD) [39].
For patients with LVEF of 35-55%, programmed electrical stimulation (PES) could help in the
risk stratification of these patients. In a study by Mehta et al, PES helped identify patients at
risk of ventricular arrhythmias and only 1 of the 68 patients with negative PES died over 5 yrs
[41]. In another series by Aizer et al, PES was predictive of arrhythmic events and ICD therapy;
however 2 of the 20 patients with negative PES died or had spontaneous sustained VT during
follow up [42]. Currently, PES is used for risk stratification, but the negative predictive value
of programmed electrical stimulation needs further study and the clinician needs to utilize
knowledge of the published literature as well as clinical judgment when considering ICD
therapy for primary prevention of SCD in sarcoidosis patients with LVEF of 35-55%.
There are no randomized trials for the prevention of sudden cardiac death in patients with
cardiac sarcoidosis, and most of the efficacy is obtained from the experience of tertiary care
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centers. In a retrospective study of patients with sarcoidosis who received ICD therapy,
inappropriate shocks were low (13.3%) and appropriate shocks occurred in 37.8%, with an
annual incidence of 15% per year. Most of the event occurred in the first 3 years post implan‐
tation [43]. In another study of 112 patients with cardiac sarcoidosis that had ICD implantation,
32% had appropriate ICD therapy and 14% had VT storm. Inappropriate therapies occurred
in 11% of patients [44]. Depressed LVEF, Depressed RVEF and complete heart block were
important predictors of appropriate ICD therapies [44].
For patients who have frequent shocks due to ventricular tachycardia, catheter ablation could
be used for treatment of these VTs. The mechanism of VT in patients with sarcoidosis is mostly
due to reentry or triggered activity. Reentry is the most common mechanism and could be due
to slow conduction from active inflammation or from scar formation. Most of these circuits are
near the basal right ventricle near the tricuspid valve area and most patients have a dramatic
decrease in the VT burden or complete elimination of the VTs following ablation [45].
Some patients with cardiac sarcoidosis progress to advanced heart failure and might need
heart transplantation. Patients with sarcoidosis have a good 1 and 5-year survival rates post
transplantation [46]. Some of the patients were only diagnosed with cardiac sarcoidosis at the
time of transplantation, underscoring the difficulties clinicians face in establishing the
diagnosis of cardiac sarcoidosis [25].
3. Arrhythmogenic Right Ventricular Dysplasia/ Cardiomyopathy
(ARVD/C)
3.1. Epidemiology
Arrhythmogenic right ventricular Dysplasia/ Cardiomyopathy (ARVD/C) is an inherited
myopathy characterized by fibrofatty infiltration of the right ventricular (RV) wall, with left
ventricular involvement over time in some patients [47, 48]. Males are more commonly affected
than females. The true prevalence of the disease is unknown, but familial involvement is seen
in up to 50%, which means screening family members is essential. The overall incidence is
thought to be 1:1000 to 1:5000, with certain regions in Greece and Italy having increased
prevalence compared to the rest of the world [49].
3.2. Environmental and genetic factors
There is no clear environmental cause of ARVD/C, and the etiology is not fully understood.
Family members of patients with ARVD/ C are affected in 30-50% of the time, and the disease
has autosomal dominant inheritance with variable penetrance. Several genetic loci have been
identified, and mostly are mutations in cardiac desmosomes. Desmosomes are membrane
structures composed of plasma cell membrane proteins that are responsible for force trans‐
mission between the cells. Abnormal function of these structures leads to cell detachment,
death and inflammatory reaction leading to fibrosis and fatty infiltration. The most common
mutation involves the PKP2 gene, encoding the plakophilin 2. Other desomsomal mutations
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were identified in DSP gene, encoding desmoplakin, DSG2 gene, encoding desmgelin 2 and
DSC2 gene, encoding desmocolin 2. Desmosomal mutations occur in 52% of North Americans
with ARVD/C and are associated with ventricular tachycardia and younger age of presentation
[50]. There is genetic variability that occurs in healthy subjects, and has been noted to be as
high as 16%. However, certain mutations make the diagnosis of ARVD/C more likely,
including radical mutations as well as certain missense mutations that are rare in Caucasians
[51]. The autosomal recessive form is associated with woolly hair and palmoplantar keratosis,
the so-called Naxos disease, since it was discovered in the Greek island of Naxos. This gene
encodes plakoglobin and desmoplakin. This autosomal recessive form has been mapped to
chromosome 17q21. In addition, the cardiac ryanodine receptor gene RyR2 may be involved
in the disease and causes juvenile sudden death with minimal RV wall motion abnormalities
[52]. Mutations in the transforming growth factor B3 (TGF-B3) were also found in a large family
in ARVD/C [53].
3.3. Pathology
The hallmark of ARVD/C is fibrofatty infiltration of the RV wall. This occurs in the epicardial
layers first and moves endocardially. The RV inflow, RV apex and RV outflow are typically
affected, forming what is called the triangle of dysplasia.  With time, the interventricular
septum is affected too. LV involvement has been described and could be seen in up to 76%
of patients [54].  It  usually parallels  right ventricular involvement and is  associated with
worse prognosis [55]. Table 3 shows the major and minor pathological criteria used by the
Task Force for diagnosis [56]. Endomyocardial biopsy doesn’t have high sensitivity, since
it is usually performed in the interventricular septum rather than the RV free wall. However,
endomyocardial  biopsy  might  help  exlude  other  disease  that  could  mimic  ARVD/C,
especially sarcoidosis. [57]
3.4. Clinical presentation
The clinical course is variable and most patients present before age 40. Patients with ARVD/C
can be asymptomatic for years. The most common clinical presentation is with palpitations
(due to frequent ventricular ectopy and ventricular tachycardia), chest pain, syncope and
sudden cardiac death. In fact sudden cardiac death could be the first manifestation of the
disease [54]. With time patients might develop RV dilatation leading to symptoms and signs
of right-sided heart failure including fatigue, abdominal fullness and lower extremity edema.
LV involvement leads to systolic heart failure and is associated with worse prognosis [58].
3.5. Electrocardiographic changes in ARVD/C
Patients with ARVD usually have sinus rhythm. The Task force criteria specify some depola‐
rization abnormalities as major criteria for diagnosis, namely the presence of Epsilon wave
(which could be seen in up to 30%, very specific but is not sensitive). If the ECG is highly
amplified, Epsilon potentials could be detected in as many as 77% of patients with ARVD [59].
Repolarization abnormalities considered to be major criteria are inverted T waves in V1 to V3
or beyond in the absence of right bundle branch block (RBBB) [56, 60]. T wave inversion in V1
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to V4 in the presence of RBBB is considered minor criteria for diagnosis. QRS fragmentation,
defined as deflections at the beginning of the QRS, on top of the R wave or at the nadir of the
S wave, could be found in as many as 85% of patients with ARVD/C and it correlates with LV
involvement [59]. Signal average electrocardiography is simple and non-invasive method that
could be used for screening. Abnormalities on signal average ECG considered to be minor
criteria are listed in Table 3.
Patients with ARVD/C can have ventricular tachycardia and frequent premature ventricular
contractions (PVCs). Ventricular tachycardia in general has left bundle branch morphology
and is caused by macro-reentry. There is evidence that adrenergic stimulation acts as a trigger
for these arrhythmias [61]. Exercise testing can induce these arrhythmias in 50-60% of ARVD/
C patients. These arrhythmias could lead to syncope and SCD. In fact, ARVC/D accounts for
3 to 10% of death occurring in patients younger than 65 years [62] and is one of the causes of
sudden cardiac death in athletes [63]. Patients with ARVD/D should not participate in
moderate to high intensity exercise [64].
Ventricular tachycardia with left bundle branch (LBB) morphology and inferior axis is
considered minor criteria, while VT with LBB morphology and superior axis is considered
major criteria. Hoffmayer et al proposed criteria to differentiate idiopathic right ventricular
outflow tract VT from ventricular tachycardia caused by ARVD/C. Since both conditions could
present with ventricular tachycardia with left bundle branch morphology with inferior axis.
In multivariate analysis, prolonged QRS duration in Lead I > 120 msec and transition in V5 or
later predicted ARVD/C as the cause of VT [65]. Table 3 lists major and minor electrocardio‐
graphic and arrhythmia criteria for diagnosis of ARVD/C [56].
Major Criteria Minor Criteria
Global and/or
regional
dysfunction
and structural
alterations
By 2D echo:
1) Regional RV akinesia, dyskinesia, or
aneurysm
2) and 1 of the following (end diastole):
• PLAX RVOT ≥32 mm (corrected for body
size [PLAX/BSA] ≥19 mm/m2)
• PSAX RVOT ≥36 mm (corrected for body
size [PSAX/BSA] ≥21 mm/m2)
• fractional area change ≤33%
By MRI:
1) Regional RV akinesia or dyskinesia or
dyssynchronous RV contraction
2) and 1 of the following:
• Ratio of RV end-diastolic volume to BSA
≥110 mL/m2 (male) or ≥100 mL/m2 (female)
• RV ejection fraction ≤40%
By RV angiography:
By 2D echo:
1) Regional RV akinesia or dyskinesia
2) and 1 of the following (end diastole):
• PLAX RVOT ≥29 to <32 mm (corrected for
body size [PLAX/BSA] ≥16 to <19 mm/m2)
• PSAX RVOT ≥32 to <36 mm (corrected for
body size [PSAX/BSA] ≥18 to <21 mm/m2)
• fractional area change >33% to ≤40%
By MRI:
1) Regional RV akinesia or dyskinesia or
dyssynchronous RV contraction
2) and 1 of the following:
• Ratio of RV end-diastolic volume to BSA
≥100 to <110 mL/m2 (male) or ≥90 to <100
mL/m2 (female)
• RV ejection fraction >40% to ≤45%
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Major Criteria Minor Criteria
Regional RV akinesia, dyskinesia, or
aneurysm
Tissue
characterization
of walls
1) Residual myocytes <60% by
morphometric analysis (or <50% if
estimated), with fibrous replacement of the
RV free wall myocardium in ≥1 sample, with
or without fatty replacement of tissue on
endomyocardial biopsy
1) Residual myocytes 60% to 75% by
morphometric analysis (or 50% to 65% if
estimated), with fibrous replacement of the
RV free wall myocardium in ≥1 sample, with
or without fatty replacement of tissue on
endomyocardial biopsy
Repolarization
abnormalities
1) Inverted T waves in right precordial leads
(V1, V2, and V3) or beyond in individuals >14
years of age (in the absence of complete
right bundle-branch block QRS ≥120 ms)
1) Inverted T waves in leads V1 and V2 in
individuals >14 years of age (in the absence
of complete right bundle-branch block) or in
V4, V5, or V6
2) Inverted T waves in leads V1, V2, V3, and
V4 in individuals >14 years of age in the
presence of complete right bundle-branch
block
Depolarization/
conduction
abnormalities
1) Epsilon wave (reproducible low-amplitude
signals between end of QRS complex to
onset of the T wave) in the right precordial
leads (V1 to V3)
1) Late potentials by SAECG in ≥1 of 3
parameters in the absence of a QRS duration
of ≥110 ms on the standard ECG
2) Filtered QRS duration (fQRS) ≥114 ms
3) Duration of terminal QRS <40 μV (low-
amplitude signal duration) ≥38 ms
4) Root-mean-square voltage of terminal 40
ms ≤20 μV
5) Terminal activation duration of QRS ≥55
ms measured from the nadir of the S wave to
the end of the QRS, including R′, in V1, V2, or
V3, in the absence of complete right bundle-
branch block
Arrhythmias
1) Nonsustained or sustained ventricular
tachycardia of left bundle-branch
morphology with superior axis (negative or
indeterminate QRS in leads II, III, and aVF and
positive in lead aVL)
1) Nonsustained or sustained ventricular
tachycardia of RV outflow configuration, left
bundle-branch block morphology with
inferior axis (positive QRS in leads II, III, and
aVF and negative in lead aVL) or of unknown
axis
2) >500 ventricular extrasystoles per 24 hours
(Holter)
Family history
1) ARVC/D confirmed in a first-degree
relative who meets current Task Force criteria
2) ARVC/D confirmed pathologically at
autopsy or surgery in a first-degree relative
3) Identification of a pathogenic mutation†
categorized as associated or probably
1) History of ARVC/D in a first-degree relative
in whom it is not possible or practical to
determine whether the family member
meets current Task Force criteria
2) Premature sudden death (<35 years of
age) due to suspected ARVC/D in a first-
degree relative
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Major Criteria Minor Criteria
associated with ARVC/D in the patient under
evaluation
3) ARVC/D confirmed pathologically or by
current Task Force Criteria in second-degree
relative
PLAX indicates parasternal long-axis view; RVOT, RV outflow tract; BSA, body surface area; PSAX, parasternal short-axis
view
Table 3. Revised Task Force Criteria for the diagnosis of ARVD/C.
3.6. Imaging in ARVD/C
3.6.1. Right ventricular contrast angiography
Right ventricular angiography could detect wall motion abnormalities, RV dilatation and even
aneurysm formation in patients with ARVD/C. However, due to its invasive nature, difficulty
in visually assessing RV wall motion abnormalities especially in the presence of premature
contractions makes it less attractive as a diagnostic modality.
3.6.2. Echocardiography
In patients with ARVD/C, the RV could be dilated with RV wall motion abnormalities and
decreased RV function. Aneurysms could form in the RV free wall but also could be found in
the inferior wall and apex. If adequate visualization of the walls is not possible because of poor
windows, contrast injection could help overcome difficulties in delineating the RV wall. Right
ventricular outflow (RVOT) enlargement is the most common abnormality found on TTE in
patients with ARVD, and RVOT long axis dimension > 30 mm has the best sensitivity (89%)
and specificity (86%) for diagnosing ARVD/C. Trabecular derangement, sacculations and
hyper-reflective moderator band are less commonly found. Attention to regional RV wall
motion abnormalities is important and could be seen in up to 80% of patients. Impaired RV
function is seen in up to 67% of patients [66]. Occasionally, trans-esophageal echocardiography
and intracardiac echocardiography could be used for diagnosis in patients with difficult
images; however, they are more invasive. TTE is widely available, simple and non-invasive
which makes it suitable as a primary diagnostic modality and should be performed in patients
with PVCs and VT with left bundle branch block and inferior axis. Major and minor echocar‐
diographic criteria for diagnosing ARVD/C are listed in Table 3 [56].
3.6.3. Radioisotope imaging
Cardiac sympathetic innervation is decreased in patients with ARVD/C, and radioisotopes
with specific affinity to the ß receptors in the heart could help in early diagnosis. However, it
has poor spatial resolution and the sensitivity and specificity of this modality is not well
established [67]. Myocardial perfusion imaging could show decreased areas of radioisotope
uptake in the RV, which could help in patients presenting with RVOT type VT. However, it is
not widely used and doesn’t have high sensitivity or specificity. Because of all this, radioiso‐
tope imaging is not considered as first line diagnostic imaging in patients with ARVD/C.
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3.6.4. Magnetic resonance imaging
Cardiac MRI has high resolution and helps in assessment of anatomy, function and hemody‐
namics of the right and left ventricle in patients with ARVD/C. Dilatation of the RVOT area,
RV wall motion abnormalities, RV aneurysms, depress RV function and presence of fat
infiltration of the RV wall all have been described in patients with ARVD/C [68-70]. However,
MRI cannot be used in patients who have defibrillators and it depends on the experience of
the center and reader [69]. Tagged MRI helps detect regional wall motion abnormalities in the
RV and LV walls. Jain et al found that regional wall motion in the LV parallels the degree of
RV function and is present in patients with grossly normal LV function [55]. LV abnormalities
include intramyocardial fat as well as wall motion abnormalities, and could be seen in up to
27% of patients (Figure 1). Delayed enhancement MRI (DE MRI) has great sensitivity and could
show increased signal in the RV (most commonly the basal sub-tricuspid region extending
anteriorly to the RV outflow) in up to 67% of patients with ARVD/C. It is important to
differentiate epicardial fat from fat infiltration of the RV wall. In patients with ARVD/C, areas
of fat infiltration are most commonly dyskinetic. Relying on fat infiltration alone without wall
motion or quantitative assessment of the RV and without adequate testing and attention to the
task force criteria could lead to over diagnosis of ARVD/C [69]. Fat infiltration is very sensitive
(84%) but has low specificity (79%) while regional RV wall motion abnormalities and RV
enlargement are very specific but less sensitive [71]. Table 3 lists the major and minor MRI
criteria used for diagnosing ARVD/C.
3.7. Electrophysiology study and three dimensional electro-anatomical mapping
Electrophysiologic  testing with programmed electrical  stimulation (PES)  is  used for  risk
stratification of  sudden cardiac death in patients  with ARVD/C but it  has poor positive
predictive value (35 to 49%) and limited negative predictive value (49 to 74%) in predict‐
ing arrhythmias and appropriate ICD shocks [72-74]. Electroanatomical mapping could help
in detecting areas of scar in patients with ARVD/C. Corrado et al demonstrated that scar
could accurately be localized in patients with ARVD/C and usually correlates with areas
with wall motion abnormalities and fibrofatty infiltration at endomyocardial biopsy. Areas
with low voltage of < 0.5 mV are considered scar areas, while healthy tissue usually has a
voltage  of  >  1.5  mV  [75].  Areas  with  voltage  between  0.5  and  1.5  mV  are  considered
transitional zone. It is important to insure appropriate contact using either fluoroscopy or
intracardiac echocardiography and to obtain multiple points in the same area to confirm
that it is a low voltage area. Furthermore, fractionated signals can be found in areas with
low  voltage  and  is  evidence  of  slow  conduction  and  could  be  part  of  the  ventricular
tachycardia circuit. Voltage mapping can help delineate the substrate for macro-reentrant
VT  in  patients  with  ARVD  [75].  Low  voltage  areas  indicating  scar  are  noted  in  the
anterolateral RV free wall, apex, and inflow and outflow tracts of the RV and correlate with
MRI findings [76]. Even in patients with ARVD and minimal scar, prolonged endocardial
activation could be noted. In a study of 25 patients with left bundle branch VT, Tandri et
al  showed that  patients  with  ARVD/C had prolonged endocardial  activation  >  65  msec
while none of  the patients with idiopathic RVOT VT had prolonged endocardial  activa‐
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tion [77]. Electroanatomical mapping is actually more sensitive than DE MRI in detecting
areas with scar, (Figure 1). especially if the scar area is < 20% of the total RV area [78].
3.8. Diagnosis of ARVD/C
Diagnosis of ARVD/C is based on the Modified Task Force Criteria published in 2010 [56].
These criteria are specific and rely on the demonstration of structural, functional and electro‐
physiological changes to diagnose the disease. To diagnose ARVD/C, 2 major criteria, one
major and two minor criteria or 4 minor criteria need to be fulfilled. The modified criteria are
more sensitive in detecting the disease in first-degree relatives of affected members without
compromising specificity and incorporate certain pathogenic mutations as major criteria for
diagnosis. Furthermore, it offers more quantitative parameters in imaging studies for diagno‐
sis compared to the original 1994 criteria. Table 3 lists the modified criteria.
Figure 1. Representative cases of discordance between endocardial voltage mapping (EVM) and contrast-enhanced
magnetic resonance (DE-MRI). A, Lateral view of the right ventricular (RV) EVM showing electroanatomical scar (EAS)
in the RV inferobasal region and outflow tract. B and C, Basal short- and long-axis views of DE-MRI sequences showing
no signs of delayed contrast enhancement (DE) in the RV free wall. Subepicardial DE is visible in the inferior and infer‐
oseptal regions of the left ventricle (LV; white arrows). D, Lateral view of EVM showing a large EAS affecting the infer‐
obasal, anterolateral, and, partly, RV outflow tract region. E and F, Basal short- and long-axis views of DE MRI showing
neither RV nor LV DE. (From Martina Perazzolo Marra, MD, PhD et al “Imaging Study of Ventricular Scar in Arrhythmo‐
genic Right Ventricular Cardiomyopathy / Clinical Perspective : Comparison of 3D Standard Electroanatomical Voltage
Mapping and Contrast-Enhanced Cardiac Magnetic Resonance” Circulation: Arrhythmia and Electrophysiology. 2012;
5: 91-100, With Permission)
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3.9. Therapy
Therapy of  ARVD/C aims at  suppressing ventricular arrhythmias,  prevention of  sudden
cardiac death and treatment of right and/or left ventricular heart failure. Family members
should  be  screened  for  the  disease  since  most  of  the  cases  have  autosomal  dominant
inheritance.
Patients  with  ARVD/C  should  not  participate  in  competitive  sports  and  should  avoid
moderate to high intensity exercise. And since the occurrence of ventricular tachycardia is
related to adrenergic stimulation, most of the patients with ARVD/C with sustained and
NSVT are typically treated with β-blockers and given antiarrhythmic drugs.  Sotalol  was
thought to suppress ventricular arrhythmias in patients with ARVD/C and is widely used
in this population [79]. However, a recent publication from the North American ARVD/C
registry  showed  that  sotalol  did  not  suppress  ventricular  arrhythmias  or  prevent  ICD
therapies while amiodarone had a better efficacy but only 10 patients received amiodar‐
one in this registry [80]. In patients with heart failure, β-blockers, angiotensin converting
enzyme inhibitors  and angiotensin receptor blockers  are indicated.  Catheter  ablation for
ventricular  arrhythmias  is  used  to  treat  sustained  ventricular  tachycardia  that  lead  to
syncope and ICD shocks in patients  with ARVD/C.  Both activation mapping as  well  as
substrate mapping could be used to delineate the VT circuit [81]. The success rate of catheter
ablation ranges from 32 to 88%, and most  patients  require  two or  three ablation proce‐
dures [82, 83]. For prevention of sudden cardiac death, implantable cardioverter defibrilla‐
tors (ICDs) are clearly indicated in patients with ARVD/C who survive cardiac arrest or
have sustained VT. It is considered a class IIa indication in ARVD/C patients with one or
more  risk  factors  of  sudden  cardiac  death  (unexplained  syncope,  presence  of  nonsus‐
tained  VT  on  ambulatory  monitoring,  extensive  RV  involvement,  LV  involvement  and
positive EPS study) [39]. However, there is no clear consensus on the risk factors for SCD
in patients with ARVD/C, and the physician needs to utilize knowledge, experience and
clinical judgment when considering ICD implantation for patients with this disease.
Since this is a young population, they are also likely to experience inappropriate shocks due
to sinus tachycardia or other supraventricular arrhythmias especially atrial fibrillation.
Inappropriate shocks occur frequently and could happen in 16 to 24% of patients [72-74].
Appropriate ICD shocks occur in 25 to 50% of patients with no prior VT or VF [74, 84]. Most
therapies are clustered early, especially in the first 2 years [43]. Syncope, inducibility at EP
study, left ventricular involvement, presence of non-sustained ventricular tachycardia or >
1000 PVCs at holter monitoring are important predictors of appropriate ICD therapy [73, 84].
Furthermore, due to the progressive nature of the disease, lead complications could occur late
and lead repositioning or implantation of a new lead are not uncommon and could occur in
14% to 21% of patients [72, 73]. In general ICD therapy is life saving and is well tolerated and
has become accepted standard of care in patients with ARVD/C who experience cardiac arrest,
sustained VT, unexplained syncope or marked RV dilatation or LV involvement [39].
Prognosis is dependent on the rate of progression of the disease, presence of heart failure and
the degree of LV involvement [85]. The diagnosis of ARVD/C should prompt genetic testing
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to identify the mutation involved and guide the screening of family members. Heart Trans‐
plantation is indicated in patients with advanced right and/or left sided heart failure.
4. Isolated left ventricular non-compaction
4.1. Introduction
Noncompaction of the left ventricular myocardium is a rare disorder that occurs in isolation
or with other congenital cardiac defects. It is caused by the arrest of compaction of the
myocardial fibers, leading to prominent trabeculations giving the myocardium a spongy
appearance. Patients can be asymptomatic and could present with syncope, chest pain,
palpitations, shortness of breath and sudden cardiac death. Management of patients with
isolated left ventricular non-compaction (ILVNC) involves treating heart failure, protection
from sudden cardiac death, anticoagulation to prevent thromboembolic events, and screening
of family members.
4.2. Epidemiology
The true prevalence of isolated LV noncompaction is unknown, as most cases are referred to
tertiary care centers. In clinical series, the prevalence ranges from 0.05 to 0.25%. The median
age at diagnosis ranges from 90 days to 45 years and males are more commonly affected than
females [86-89].
4.3. Pathology
Noncompaction of the left ventricular myocardium is caused by the arrest of intrauterine
compaction of the myocardial fibers, leading to prominent trabeculations giving the myocar‐
dium a spongy appearance [90]. It is often associated with other congenital cardiac anomalies,
especially obstruction of the right or left ventricular outflow tracts. However, the deep
intertrabecular recesses that persist in these cases are in communication with the ventricular
cavity and the coronary circulation [87]. In contrast, the intertrabecular recesses in isolated LV
noncompaction are in communication with the LV cavity only and not with the coronary
circulation. Histologically, there is myocardial thickening as well as interstitial and subendo‐
cardial fibrosis [91]. Microcirculatory dysfunction is present in both compacted and noncom‐
pacted segments which might explain the subendocarial scar noted on biopsies as well as the
wall motion abnormalities noted in imaging [92].
4.4. Genetics
Familial involvement was high in initial reports describing isolated LV noncompaction [93] In
later series involving adults, the familial recurrence ranged from 12 to 44%. Some mutations
involving the G4.5 gene have X linked Inheritance [94, 95]. However, autosomal dominant
inheritance has also been reported with mutations in chromosome 11p15 [95, 96].
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Sarcomere protein gene defects are also found in patients with ILVNC. Mutations in cipher/
ZASP, a gene encoding for the Z-band, can cause dilated cardiomyopathy as well as ILVNC
[97]. In a study of 63 unrelated patients with ILVNC, mutations in genes encoding sarcomere
proteins were identified in 11 patients. These genes include β myosin heavy chain (MYH7),
α-cardiac actin and cardiac troponin T. Similar sarcomere gene mutations, especially in MYH7
are also found in patients with hypertrophic and dilated cardiomyopathies [98]. These
sarcomere mutations could account for up to 29% of mutations in ILVNC, but they do not
predict clinical outcome [99].
4.5. Clinical presentation
Patients with isolated LV noncompaction can be asymptomatic for years and eventually could
present with heart failure, arrhythmias, embolic events and sudden cardiac death. The clinical
course is variable, with patients who are asymptomatic having a more stable clinical course,
while patients presenting with heart failure having a progressive clinical course with heart
failure and ventricular arrhythmias [100]. Most patients have some degree of LV dysfunction,
which has been reported in up to 60% of patients in the four largest reports of LV noncom‐
paction [86, 87, 93, 101]. However, presentation as congestive heart failure with dyspnea on
exertion has ranged from 30–68%. Patients could have systolic as well as diastolic dysfunction.
Microcirculatory dysfunction could lead to ischemia and scar causing wall motion abnormal‐
ities and systolic heart failure. While impaired filling and abnormal relaxation from prominent
trabeculations could lead to diastolic heart failure [92]. Several arrhythmias have been reported
with ILVNC, including atrial fibrillation (5–29% in major reports), atrial tachycardia, prema‐
ture ventricular complexes and ventricular tachycardia (18–47% in major reports). Sudden
cardiac death accounted for 50% of deaths in ILVNC. Presence of subendocardial scar can act
as a substrate of reentry in these patients. Embolic complications in ILVNC could be due to
thrombus formation in the recesses of the trabeculations, due to stagnant flow from severely
depressed LV function or from atrial fibrillation. These emboli can go to the cerebrovascular
circulation, peripheral circulation, or pulmonary circulation. The incidence of embolization
has ranged from 21–38%. Anticoagulation to prevent thromboembolic complications is very
important in ILVNC [91].
4.6. Electrocardiogram
Abnormalities noted in the electrocardiogram in patients with ILVNC include left bundle
branch block, right bundle branch block, left ventricular hypertrophy with repolarization
abnormalities, and AV block. Wolff-Parkinson-White syndrome has been described in children
with ILVNC. Atrial fibrillation, frequent premature ventricular contractions with sustained
and non-sustained ventricular tachycardia could be present and could be the first presentation
of the disease. There is a high prevalence of early repolarization in patients with ILVNC,
especially in those patients who present with malignant arrhythmias [86, 87, 102].
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4.7. Imaging in isolated left ventricular non-compaction
4.7.1. Echocardiography
Transthoracic echocardiography is the modality most commonly used to diagnose ILVNC
[103]. The most common criteria used for diagnoses have been proposed by Jenni et al, with a
ratio of noncompacted to compacted LV myocardium of 2 to 1 considered diagnostic [104].
This is typically measured at end systole in the parasternal short axis view. Deep intertrabec‐
ular recesses that are supplied from the LV cavity and absence of other congenital anomalies
are part of Jenni’s criteria. However, some experts suggest the ratio of noncompacted to
compacted myocardium should be measured but in the parasternal short axis view at end
diastole [103]. Chin et al proposed a measurement of compacted myocardium (C) to the total
thickness of both compacted and noncompacted layers (C + NC) at end diastole, with the ratio
of C/ (NC+C) of < 0.5 considered diagnostic. However, there is poor agreement between readers
when it comes to the ratio of noncompated to compacted myocardium, with only 74% of
agreement noted and there is poor agreement between these two criteria for diagnosis [105].
Jenni’s criteria are more specific while Chin’s criteria are more sensitive. In general the
noncompacted segments most commonly involve the apex more than the base, and are seen
mostly in the inferior wall and also in the lateral wall [104]. Multiple segments are usually
involved (Figure 2). The right ventricle is involved in 40% of the cases [89, 105]. Wall motion
abnormalities, impaired diastolic filling as measured from mitral inflow velocities are also
seen. Depressed LV ejection fraction is noted in a lot of patients with LV noncompaction, and
patients with severe LV dysfunction have a poor prognosis. It is important to differentiate
ILVNC from hypertrophic cardiomyopathy (especially the apical variant), dilated cardiomy‐
opathy, arrhythmogenic right ventricular dysplasia and endocardial fibroelastosis. But in
isolated LVNC, perfused recesses and hypokinetic segments are very specific, and the wall
thickening noted is confined to certain walls of the LV. Visualization of the trabecular recesses
could be enhanced using contrast. Transesophageal echocardiography could also be used in
diagnoses in patients with difficult windows.
4.7.2. Magnetic Resonance Imaging (MRI)
Magnetic resonance imaging (MRI) has been also used for diagnosis. Delayed gadolinium
enhancement has been seen in both compacted and noncompacted myocardium. In compacted
myocardium, delayed enhancement correlated well with fibrosis, while in the noncompacted
segments, delayed enhancement correlated with fibrosis as well as mucoid degeneration of
the endocardium [106]. MRI offers better spatial resolution and can help assess LV and RV
functions, wall motion abnormalities, as well as the ratio of compacted and noncompacted
segments, which has been shown to be an important predictor of major adverse cardiac events,
including heart failure, ventricular arrhythmias and thromboembolism. A ratio of noncom‐
pacted to compacted myocardium of > 2.3 at end diastole had the best sensitivity (86%) and
specificity (99%) in diagnosing ILVNC [107]. However, 140 patients (43%) of 323 patients in
the MESA cohort had at least one area with trabeculated to compact ratio of > 2.3 and the
authors advised caution in using these criteria alone for diagnosis of ILVNC [108]. The
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calculation of trabeculated LV mass using MRI could help also in the diagnosis of ILVNC, with
trabeculated LV mass of > 20% of the total LV mass having the highest sensitivity and specificity
(93.7%) in diagnosing ILVNC [109].
4.7.3. Other imaging modalities
Computed tomography scan could be used to diagnose ILVNC and has high spatial resolution.
Prominent trabeculations as well as deep intertrabecular recesses are typically seen [103].
Contrast ventriculography could also be used but is invasive. PET scan could show decreased
myocardial flow reserve in noncompacted areas as well as microcirculatory dysfunction in
both compacted and noncompacted myocardium but this has limited utility in establishing
the diagnosis [92, 110]. To date, Echocardiography and MRI remain the most common
modalities used for diagnosing ILVNC.
4.8. Therapy
Management of patients with ILVNC involves treating heart failure, protection from sudden
cardiac death, anticoagulation to prevent thromboembolic events, and screening of family
members. β-blockers, angiotensin converting enzyme inhibitors and angtiotensin receptor
blockers are used and have been reported to improve symptoms and the LVEF [111]. Antico‐
agulation with coumadin is recommended in all patients, even if they don’t have atrial
fibrillation. Electrophysiology testing to predict the risk of sudden cardiac death has not
Figure 2. Apical 2 chamber view showing prominent trabeculations in the apex and inferior walls consistent with Iso‐
lated Left Ventricular Non-Compation.
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yielded great results. Currently, the decision to implant a defibrillator (ICD) or biventricular
defibrillator (BiV ICD) is clear in patients who have survived a cardiac arrest or in patients
with LVEF <35% who qualify for an ICD or BIV ICD according to the current guidelines [39].
In a series of 30 patients with ILVNC who received ICDs or BiV ICDs according to the current
guidelines, Kobza et al showed that appropriate ICD therapy (either shocks or antitachycardia
pacing) occurred in 37% of cases with a mean follow up of 21 ± 16 months. Inappropriate shocks
occurred in 13% of cases. In patients who received ICD therapy for primary prevention, 33%
had appropriate ICD therapy with mean follow up of 27 ± 33 months. There were no predictors
of appropriate ICD therapy [112].
The prognosis of ILVNC varies. Initial reports were based on the experience in tertiary care
centers led to the belief that the prognosis is poor, with progressive heart failure leading to
death or transplantation in 47% of adults with ILVNC followed for 44 ± 39 months [91].
However, recent reports challenge this and asymptomatic patients in general have a good
prognosis [113]. Certain clinical characteristics are more common in non-survivors compared
to survivors, including higher LV end-diastolic diameter, New York Heart Association class
III–IV heart failure, left bundle branch block, and persistent atrial fibrillation. Patients with
such clinical characteristics need frequent follow up, with strong consideration for more
aggressive treatment [86]. Family screening is important, with transthoracic echocardiography
being the most common screening modality. Family members may have other forms of
cardiomyopathy, like dilated or hypertrophic cardiomyopathy [113]. Recent advances in
genetic testing will allow identification of the genetic mutation in the proband and help narrow
the search for the genetic mutations.
5. Conclusion
Cardiac Sarcoidosis, arrhythmogenic right ventricular dysplasia and isolated left ventricular
noncompaction are rare forms of cardiomyopathy that affect young patients and put them at
risk of sudden cardiac death. Early recognition and treatment is important. In the absence of
clear guidelines to prevent sudden cardiac death in this young population, the clinician should
use current knowledge, clinical judgment and expertise when treating these patients. Advan‐
ces in diagnostic imaging as well as genetic testing will help early diagnosis and identification
of affected family members.
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